tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

XORTX Therapeutics Completes US$925,000 Private Placement to Fund Gout Programs

Story Highlights
XORTX Therapeutics Completes US$925,000 Private Placement to Fund Gout Programs

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

XORTX Therapeutics Inc ( (TSE:XRTX) ) has shared an announcement.

XORTX Therapeutics Inc. announced the completion of a non-brokered private placement of units, raising gross proceeds of US$925,000. Each unit consists of one common share and one warrant, with the proceeds intended for gout programs and general corporate purposes. The placement was approved by the TSX Venture Exchange, and the securities issued will not be subject to a statutory hold period. The announcement also noted that a previously announced private placement from May 2025 will not proceed. This development could enhance XORTX’s financial position and support its ongoing research and development efforts.

The most recent analyst rating on (TSE:XRTX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.

Spark’s Take on TSE:XRTX Stock

According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.

XORTX Therapeutics Inc faces significant challenges with no revenue and consistent losses, leading to a low financial performance score. Technical analysis indicates a neutral to bearish outlook, which, along with poor valuation metrics, weighs down the overall stock score. However, potential advancements in FDA discussions for gout treatment provide a glimmer of hope for future revenue generation, but current financial and compliance risks remain substantial.

To see Spark’s full report on TSE:XRTX stock, click here.

More about XORTX Therapeutics Inc

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for the treatment of gout and progressive kidney disease. The company has three clinically advanced products in development, including XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney and organ injury associated with respiratory virus infections. Additionally, XORTX is working on a pre-clinical program, XRx-225, for Type 2 diabetic nephropathy, targeting aberrant purine metabolism and xanthine oxidase to decrease uric acid production.

Average Trading Volume: 3,526

Technical Sentiment Signal: Sell

Current Market Cap: C$4.85M

For an in-depth examination of XRTX stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1